<VariationArchive VariationID="639496" VariationName="NM_000387.6(SLC25A20):c.804del (p.Phe269fs)" VariationType="Deletion" Accession="VCV000639496" Version="4" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-02-20" DateCreated="2019-08-14" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="631499" VariationID="639496">
      <GeneList>
        <Gene Symbol="SLC25A20" FullName="solute carrier family 25 member 20" GeneID="788" HGNC_ID="HGNC:1421" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>3p21.31</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="48856926" stop="48898882" display_start="48856926" display_stop="48898882" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="48894355" stop="48936425" display_start="48894355" display_stop="48936425" Strand="-" />
          </Location>
          <OMIM>613698</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000387.6(SLC25A20):c.804del (p.Phe269fs)</Name>
      <CanonicalSPDI>NC_000003.12:48858545:CCC:CC</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3p21.31</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="48858546" stop="48858546" display_start="48858546" display_stop="48858546" variantLength="1" positionVCF="48858545" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="48895979" stop="48895979" display_start="48895979" display_stop="48895979" variantLength="1" positionVCF="48895978" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>F269fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.48895981del" Assembly="GRCh37">
            <Expression>NC_000003.11:g.48895981del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.48858548del" Assembly="GRCh38">
            <Expression>NC_000003.12:g.48858548del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008171.1" sequenceAccession="NG_008171" sequenceVersion="1" change="g.45351del">
            <Expression>NG_008171.1:g.45351del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000387.6" sequenceAccession="NM_000387" sequenceVersion="6" change="c.804del" MANESelect="true">
            <Expression>NM_000387.6:c.804del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000378.1" sequenceAccession="NP_000378" sequenceVersion="1" change="p.Phe269fs">
            <Expression>NP_000378.1:p.Phe269fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000387.5" sequenceAccession="NM_000387" sequenceVersion="5" change="c.804delG">
            <Expression>NM_000387.5:c.804delG</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="753414360" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000387.6(SLC25A20):c.804del (p.Phe269fs) AND Carnitine acylcarnitine translocase deficiency" Accession="RCV000792302" Version="4">
        <ClassifiedConditionList TraitSetID="3286">
          <ClassifiedCondition DB="MedGen" ID="C0342791">Carnitine acylcarnitine translocase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-11-27" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-11-27" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2019-08-14" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12559850</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15365988</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21605995</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24088670</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33634872</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">35360862</ID>
        </Citation>
        <DescriptionHistory Dated="2024-02-11">
          <Description>Pathogenic/Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2020-06-22">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="3286" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10955" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Carnitine acylcarnitine translocase deficiency</ElementValue>
                <XRef ID="Carnitine-Acylcarnitine+Translocase+Deficiency/1115" DB="Genetic Alliance" />
                <XRef ID="238003000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CACTD</ElementValue>
                <XRef Type="MIM" ID="212138" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Carnitine-acylcarnitine translocase (CACT) is a critical component of the carnitine shuttle, which facilitates the transfer of long-chain fatty acylcarnitines across the inner mitochondrial membrane. CACT deficiency causes a defect in mitochondrial long-chain fatty acid ß-oxidation, with variable clinical severity. Severe neonatal-onset disease is most common, with symptoms evident within two days after birth; attenuated cases may present in the first months of life. Hyperammonemia and cardiac arrhythmia are prominent in early-onset disease, with high rates of cardiac arrest. Other clinical features are typical for disorders of long-chain fatty acid oxidation: poor feeding, lethargy, hypoketotic hypoglycemia, hypotonia, transaminitis, liver dysfunction with hepatomegaly, and rhabdomyolysis. Univentricular or biventricular hypertrophic cardiomyopathy, ranging from mild to severe, may respond to appropriate dietary and medical therapies. Hyperammonemia is difficult to treat and is an important determinant of long-term neurocognitive outcome. Affected individuals with early-onset disease typically experience brain injury at presentation, and have recurrent hyperammonemia leading to developmental delay / intellectual disability. Affected individuals with later-onset disease have milder symptoms and are less likely to experience recurrent hyperammonemia, allowing a better developmental outcome. Prompt treatment of the presenting episode to prevent hypoglycemic, hypoxic, or hyperammonemic brain injury may allow normal growth and development.</Attribute>
                <XRef ID="NBK582032" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="1123" />
                <XRef ID="1123" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">35862567</ID>
                <ID Source="BookShelf">NBK582032</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Carnitine-Palmitoyltransferase-2-Deficiency-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased C16 and/or C18:1 Acylcarnitine, Carnitine Palmitoyltransferase II (CPT II) Deficiency and Carnitine Acylcarnitine Translocase (CACT) Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C16-C18-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, C16 +/- C18:1 Elevated: CPT II or CACT, 2022</CitationText>
              </Citation>
              <XRef ID="159" DB="Orphanet" />
              <XRef ID="C0342791" DB="MedGen" />
              <XRef ID="MONDO:0008918" DB="MONDO" />
              <XRef Type="MIM" ID="212138" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2669541" SubmissionDate="2020-03-06" DateLastUpdated="2020-06-22" DateCreated="2020-06-22">
        <ClinVarSubmissionID localKey="NM_000387.5:c.804del|MedGen:C0342791" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001361222" DateUpdated="2020-06-22" DateCreated="2020-06-22" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-02-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12559850</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21605995</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24088670</ID>
          </Citation>
          <Comment>Variant summary: The variant, SLC25A20 c.804delG (p.Phe269SerfsX4) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 7.2e-06 in 277230 control chromosomes (gnomAD) and has been reported in the literature in individuals affected with Carnitine-Acylcarnitine Translocase Deficiency (Costa _2003, Wang _2011). These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in &lt;10% of normal activity (Costa _2003). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A20" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000387.5:c.804del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Carnitine acylcarnitine translocase deficiency</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0342791" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6913290</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1825352" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="4647906|MedGen:C0342791" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000931589" DateUpdated="2024-02-14" DateCreated="2019-08-14" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12559850</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21605995</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33634872</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">35360862</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15365988</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Phe269Serfs*4) in the SLC25A20 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 33 amino acid(s) of the SLC25A20 protein. This variant is present in population databases (rs753414360, gnomAD 0.008%). This premature translational stop signal has been observed in individuals with carnitine-acylcarnitine translocase deficiency (PMID: 12559850, 21605995, 33634872, 35360862). This variant is also known as c.802delG. ClinVar contains an entry for this variant (Variation ID: 639496). This variant disrupts the C-terminus of the SLC25A20 protein. Other variant(s) that disrupt this region (p.Ala281Val) have been observed in individuals with SLC25A20-related conditions (PMID: 15365988). This suggests that this may be a clinically significant region of the protein. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A20" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.48895979del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0342791" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB5371970</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2669541" TraitType="Disease" MappingType="Name" MappingValue="Carnitine acylcarnitine translocase deficiency" MappingRef="Preferred">
        <MedGen CUI="C0342791" Name="Carnitine acylcarnitine translocase deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1825352" TraitType="Disease" MappingType="XRef" MappingValue="C0342791" MappingRef="MedGen">
        <MedGen CUI="C0342791" Name="Carnitine acylcarnitine translocase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

